No abstract available.
Cocaine* ; Levamisole* ; Purpura*

Kimura's disease is a chronic inflammatory soft tissue disorder with peripheral eosinophila and high serum IgE. It might be associated with nephrotic syndrome. We report a 6-year-old boy with Kimura's disease and the concurrent steroid dependant minimal change nephrotic syndrome. With levamisole treatment fot 24 months, tumor progression and relapse of the associated nephrotic syndrome were not observed.
Child ; Humans ; Immunoglobulin E ; Levamisole ; Nephrosis, Lipoid ; Nephrotic Syndrome ; Recurrence

Levamisole has been used for nephrotic syndrome due to its immunostimulating, immunomodulating, and steroid-sparing effects. Agranulocytosis, a serious side effect of levamisole, was rare and mostly associated with autoimmune disease, neoplastic disease and HLA B27 except one case in a nephrotic syndrome who was treated with high-dose(5mg/kg QOD) levamisole. This 15 year-old girl with steroid dependent nephrotic syndrome, who was negative for HLA B27, was treated with the usual recommended dose of levamisole(2.5mg/kg QOD). She developed agranulocytosis after 5 weeks of therapy and completely recovered in 11 days after discontinuation of levamisole.
Adolescent ; Agranulocytosis* ; Autoimmune Diseases ; Child* ; Female ; Humans ; Levamisole ; Nephrotic Syndrome*

BACKGROUND: Several different kinds of drugs have been used to treat chronic oral lichen planus (OLP). During the last decade, there have been several reports demonstrating success with levamisole and low dose prednisolone therapy for treating OLP. However, some OLP patients who have underlying diseases such as diabetes, hypertension and malignancy are unable to take steroids. OBJECTIVE: The aim of this study was to evaluate levamisole monotherapy for treating OLP. METHODS: Eleven patients who had OLP were treated with levamisole between 2005 and 2007. The levamisole was administered at a dose 50 mg thrice daily for three consecutive days, but then it was not administered on the following four days. RESULTS: After 2 weeks of treatment, 8 patients reported a partial response, 3 patients reported no response and no patients reported clearance of lesion. After 4 weeks of treatment, 6 patients reported a partial response, 3 patients reported no response and 2 patients reported clearance of lesion. Furthermore, after 3 months of treatment, 3 patients reported a partial response, 3 patients reported no response and 5 patients reported complete clearance of lesion. Clinical improvement was shown in 2 weeks, whilst the mean duration to achieve clearance of lesion was 6.2 weeks. Although 1 patient had mild itching, there were no significant adverse effects. CONCLUSION: Levamisole monotherapy could be a successful and safe treatment option for patients with chronic OLP and who cannot take steroids.
Humans ; Hypertension ; Levamisole ; Lichen Planus, Oral ; Prednisolone ; Pruritus ; Steroids

BACKGROUND: There are few therapeutic options in patients with colorectal cancer that progressed or recurred after initial 5-fluorouracil (5-FU) therapy. Many different 5-FU-based regimens and biochemical modulations that can potentiate the cytotoxic effects of 5-FU have been investigated in these patients. We evaluated the efficacy and toxicity of combination of 5-FU, leucovorin, levamisole and cisplatin(FLLP) salvage combination chemotherapy in progressive or recurrent colorectal cancer after 5-FU/leucovorin chemotherapy. METHODS: Twenty-eight patients were enrolled in this study from April 1995 to July 1999. Patients received cisplatin (60 mg/m2) administerd on day 1, followed by leucovorin (20 mg/m2) and 5-FU (375 mg/m2) by rapid intravenous push for 5 consecutive days on day 1~5. Levamisole was given orally at a dose 50 mg three times a day on day 1~3 & day 15~17. Treatment courses were repeated in 4-week intervals. RESULTS: Twenty-two patients were evaluable after treatment. Objective tumor response was in 4 of 22 (18.2%). The complete response, partial response, stable disease were 4.5% (1/22), 13.7% (3/22), 31.8% (7/22) respectively. The median response duration was 5.5 months. The median time to progression was 5.8 months. The overall median survival duration was 8.7 months and response group lived significantly longer than non-response group (not yet reached vs. 7.9 month, p=0.03). WHO grade 3-4 leukopenia occurred in 14%, nausea and vomiting 9%, but there was no treatment related death. CONCLUSION: We concluded that evaluation of this regimen appears relatively safe, with modest response as a salvage chemotherapy in patients who were previously exposed to 5-FU containing regimen.
Cisplatin ; Colorectal Neoplasms* ; Drug Therapy ; Drug Therapy, Combination* ; Fluorouracil* ; Humans ; Leucovorin ; Leukopenia ; Levamisole ; Nausea ; Vomiting

There have been no standard treatments for recurrent aphthous stomatitis, and clinical management is usually directed toward symptomatic relief. Recent immunological investigations have focused on possible imrnunopathogenesis of the disease. Several reparters suggested that levamisole, nonspecific immune-stimulator, had a beneficiaI effect in controlling attacks of recurrent a,phthous stomatitis and in reducing subsequent episodes. The present study was undertaken to evaluate the therapeutic effectiveness of levamisole in patients with recurrent aphthous stomatitis. A total of 8 patients who had had recurrent aphthous stomatitis for 2 to 20 years and who had experienced at least one episode per month were selected for this study from the department of dermatology, National Medical Center, through March 1979 to September 1979, Levamisole (Decaris') was given 150mg, p.o., once daily on 3 consecutive days every week for 2 months. Tbe results were as follows. 1) One patient had to have levamisole discontinued due to a high fever and exacerbations of tbe oral ulcerations. 2) 5 patients showed beneficial effects in reducing tbe number, frequency, pain and severity of recurrent aphthous stomatitis. 3') One patient showed no therapeutic response. 4) One patient, who has experienced new oral ulcerations continuously before starting levamisole, showed no recurrences of the lesions during the follow-up period of 3 months. 5) Side effects during levamisole administration were transient and generally mild, They included nausea, headache, dizziness and high fever.
Dermatology ; Dizziness ; Fever ; Follow-Up Studies ; Headache ; Humans ; Levamisole* ; Nausea ; Oral Ulcer ; Recurrence ; Stomatitis ; Stomatitis, Aphthous*

PURPOSE: Long-term use of steroid, cyclophosphamide and cyclosporin, which are frequently used in the therapy of SDNS, might cause severe side effects. Recently, the immune-modulator levamisole has been tried as a substitute therapy and it has been reported as a method with less side effects and more effectiveness. We started this research in order to observe the effects of levamisole and compare it to other therapy results. PATIENTS AND METHODS: We chose 16 steroid dependent nephrotic syndrome children, those who had shown frequent relapse during the immunocompromised therapy period. Mean age was 9.1+/-.4 years in children and the male to female ratio was 15:1. All of subjects were diagonized with MCNS and had received cyclophosphamide or cyclosporin before receiving levamisole. Levamisole at a dose of 2.5mg/kg was used every other day for 1 year and the relapse rate was observed. RESULTS: On average of 14 days after treatment, complete remission was visible in all of the children, and the relapse percentage was 50%, which represents 8 children, while remaining 8 children representing 50% of the cases showed no relapse during treatment. During the levamisole therapy period, the average relapse rate was reduced significantly from 2.18+/-.9/year to 0.77+/-.9/year(p=0.027). Also the average relapse rate after the therapy was reduced to 1.34+/-.1/year, which was a significant level compared to the level before treatment(p=0.003). There was no significant difference in terms of duration of remission maintenance. Duration of remission maintenance showed an average of 12.2+/-.1 months before the use of levamisole, but it was also 10.1+/-.9 month after therapy. No other side effects such as leukopenia, skin disease and other clinically significant symptoms appeared at all during therapy. CONCLUSION: The long-term medication of levamisole for the therapy of SDNS children is thought to be able to maintain stable remission by reducing the relapse frequency without causing severe side effects. Further study with a broader range of subjects is required to eluccidate the long-term effects of this treatment.
Child* ; Cyclophosphamide ; Cyclosporine ; Female ; Humans ; Leukopenia ; Levamisole* ; Male ; Nephrotic Syndrome* ; Recurrence ; Skin Diseases

PURPOSE: Steroid dependent nephrotic syndrome (SDNS) is a chronic illness in childhood hard to treat. Steroid sparing drugs are often used, because long-term steroid therapy can cause severe side effects. We studied to compare efficacy between MMF and other drugs including cyclosporine and levamisole. METHODS: This study was performed retrospectively on patients with SDNS, who were treated at Pusan National University Children's hospital. MMF group included 11 patients who were treated with MMF for at least six months between June 2012 and July 2014. As control groups, cyclosporine group (n=15) and levamisole group (n=18) included patients treated between January 2008 and July 2014. Number of relapse was analyzed in patients treated more than six months, and relapse free for one year was analyzed in patients treated more than one year. RESULTS: In MMF group, ten were boys and mean age at onset was 5.8 years. Mean age at starting of MMF was 8.6 years. Number of relapse in MMF group was reduced significantly after treatment from 3.4 /year to 0.2 /year (P=0.003). There was no significant difference in number of relapse among groups (MMF: 0.2 /year, cyclosporine: 0.5 /year, levamisole: 0.5 /year). Comparing the early relapse within six months after treatment levamisole group was significantly higher than the other two groups (P=0.04). CONCLUSIONS: MMF which is used in SDNS significantly reduced the relapse and side effects were rare. In addition, MMF did not show any significant difference in comparison with the other two groups in number of relapse and relapse free for one year.
Busan ; Child* ; Chronic Disease ; Cyclosporine ; Humans ; Levamisole ; Nephrotic Syndrome* ; Recurrence ; Retrospective Studies

PURPOSE: FP(5-FU, Cisplatin) combination is one of the most active regimen for the advanced gastric cancer with a response rate of 50~60%. In spite of this high response rate, there is little evidence that FP regimen results in survival benefit for patients with advanced gastric cancer. This study was performed to evaluate the efficacy and toxicity of this regimen with the addition of levamisole, an immunomodulatory agent, known as enhancing the antitumor effects of 5-FU in other cancer. MATERIALS AND METHODS: Previously untreated patients with metastatic or recurrent gastric cancer were treated with 5-FU(1000 mg/M2 civ, D1~5), cisplatin(60 mg/M2 iv, Dl) every 3 weeks, and levamisole(150 mg/day, Dl~3) every 2 weeks. The major endpoints were response rate, response duration, and toxicities. RESULTS: Between June 1992 and Aug. 1996, thirty three patients were included in this study. Patients received 2~18 cycles of chemotherapy(median 5). Among the evaluable 31 patients, 18 patients(58%, 95% C.I. 40.4~75.7) showed objective responses including one(3.2%) clinical complete response. The median response duration was 7.7 months(95% C.I. 3.6~11.8). During total of 189 cycles of chemotherapy, 79 episodes(41.7%) of leucopenia were observed. There was no death from concurrent infection. CONCLUSION: FPL combination therapy is at least as effective as conventional FP chemotherapy, but resulted in somewhat more myelosuppression.
Cisplatin* ; Drug Therapy ; Drug Therapy, Combination* ; Fluorouracil* ; Humans ; Levamisole* ; Stomach Neoplasms

We report herein a caae of linear scleroderma resembling pseudoainhum. The patient was a 17-year-old boy who has 10 years history of linear, ivory colored, atraphic patch on his left 4th finger and left arm. The lesion was progreased slowly, and 2 years before he visited our hospital, his left 4th finger was amputated spontaneously. In histopathological examination, packed collagen, thick collagen bundle in dermis, and large areas of subcutaneous fat were replaced by eollagen fiber. Diagnosis was confirmed by the characteristics of clinical features and histopathologic findings of the skin. As therapeutic trials, steroid intralesional injection, immunotherapy with levamisole, agd penicillamine were attempted.
Adolescent ; Arm ; Collagen ; Dermis ; Diagnosis ; Fingers ; Humans ; Immunotherapy ; Injections, Intralesional ; Levamisole ; Male ; Penicillamine ; Scleroderma, Localized* ; Skin ; Subcutaneous Fat